Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Epidemiology
Published in: European Journal of Epidemiology 3/2018

01-03-2018 | META-ANALYSIS

New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis

Authors: Kevin David Shield, Claire Marant Micallef, Catherine de Martel, Isabelle Heard, Francis Megraud, Martyn Plummer, Jérôme Vignat, Freddie Bray, Isabelle Soerjomataram

Published in: European Journal of Epidemiology | Issue 3/2018

Login to get access

Abstract

To provide an assessment of the burden of cancer in France in 2015 attributable to infectious agents. A systematic literature review in French representative cancer cases series was undertaken of the prevalence of infectious agents with the major associated cancer types. PubMed was searched for original studies published up to September 2016; random-effects meta-analyses were performed. Cancer incidence data were obtained from the French Cancer Registries Network, thereby allowing the calculation of national incidence estimates. The number of new cancer cases attributable to infectious agents was calculated using population-attributable fractions according to published methods. Of the 352,000 new cancer cases in France in 2015, 14,336 (4.1% of all new cancer cases) were attributable to infectious agents. The largest contributors were human papillomavirus (HPV) and Helicobacter pylori, responsible for 6333 and 4406 new cancer cases (1.8 and 1.3% of all new cancer cases) respectively. Infectious agents caused a non-negligible number of new cancer cases in France in 2015. Most of these cancers were preventable. The expansion of vaccination (i.e., for hepatitis B virus and HPV) and screen-and-treat programs (for HPV and hepatitis C virus, and possibly for H. pylori) could greatly reduce this cancer burden.
Appendix
Available only for authorised users
Literature
1.
International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: volume 100B—biological agents. Lyon, France: International Agency for Research on Cancer; 2009.
2.
3.
Antonsson A, Wilson LF, Kendall BJ, Bain CJ, Whiteman DC, Neale RE. Cancers in Australia in 2010 attributable to infectious agents. Aust N Z J Public Health. 2015;39(5):446–51.CrossRefPubMedPubMedCentral
4.
5.
International Agency for Research on Cancer. Attributable causes of cancer in France in the year 2000. Lyon: International Agency for Research on Cancer; 2007.
6.
Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev. 1997;6(6):387–400.PubMed
7.
De Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.CrossRefPubMed
8.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16.CrossRefPubMed
9.
Fonteneau L, Guthmann J, Lévy-Bruhl D. Estimation des couvertures vaccinales en France à partir de l’Échantillon généraliste des bénéficiaires (EGB): exemples de la rougeole, de l’hépatite B et de la vaccination HPV. Bull Epidemiol Hebd. 2013;8:72–6.
10.
Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43(2):223–33.CrossRefPubMed
11.
Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–9.CrossRefPubMedPubMedCentral
12.
Herrero R, Park JY, Forman D. The fight against gastric cancer–the IARC Working Group report. Best Pract Res Clin Gastroenterol. 2014;28(6):1107–14.CrossRefPubMed
13.
14.
Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1576 patients in France. Am J Hematol. 2001;67(3):168–71.CrossRefPubMed
15.
Santé Pays de la Loire. Le réseau FRANCIM: Les registres des cancers en France. Nantes: Santé Pays de la Loire; 2015.
16.
Institut national de la statistique et des études économiques. Statistical operation: Population estimates. Paris, France: Institut national de la statistique et des études économiques; 2015.
17.
Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535.CrossRef
18.
Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16 INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31.CrossRefPubMed
19.
Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
20.
R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
21.
StataCorp. Stata Statistical Software: Release 14. College Station, USA: StataCorp LP; 2015.
22.
Levy M, Hammel P, Lamarque D, et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. Gastrointest Endosc. 1997;46(4):328–33.CrossRefPubMed
23.
Delchier JC, Lamarque D, Levy M, et al. Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type. Am J Gastroenterol. 2001;96(8):2324–8.CrossRefPubMed
24.
Lehours P, Ruskone-Fourmestraux A, Lavergne A, Cantet F, Megraud F. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol. 2003;98(2):291–5.CrossRefPubMed
25.
Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23(22):5061–6.CrossRefPubMed
26.
Fouret P, Martin F, Flahault A, Saint-Guily JL. Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Diagn Mol Pathol. 1995;4(2):122–7.CrossRefPubMed
27.
Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg. 1997;123(5):513–6.CrossRefPubMed
28.
Soria JC, Morat L, Commo F, et al. Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis. Br J Cancer. 2001;84(4):504–11.CrossRefPubMedPubMedCentral
29.
Humbey O, Cairey-Remonnay S, Guerrini JS, et al. Detection of the human papillomavirus and analysis of the TP53 polymorphism of exon 4 at codon 72 in penile squamous cell carcinomas. Eur J Cancer. 2003;39(5):684–90.CrossRefPubMed
30.
Perceau G, Derancourt C, Clavel C, et al. Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus. Br J Dermatol. 2003;148(5):934–8.CrossRefPubMed
31.
Cornu JN, Comperat E, Renard-Penna R, et al. Can a standard treatment be proposed for penile cancer? Prog Urol. 2007;17(7):1347–50.CrossRefPubMed
32.
Charfi L, Jouffroy T, de Cremoux P, et al. Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. Cancer Lett. 2008;260(1–2):72–8.CrossRefPubMed
33.
Jung AC, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer. 2010;126(8):1882–94.CrossRefPubMed
34.
Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer. 2011;129(2):433–9.CrossRefPubMed
35.
36.
St Guily JL, Jacquard AC, Pretet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France—The EDiTH VI study. J Clin Virol. 2011;51(2):100–4.CrossRefPubMed
37.
Gavid M, Pillet S, Pozzetto B, et al. Human papillomavirus and head and neck squamous cell carcinomas in the South-East of France: prevalence, viral expression, and prognostic implications. Acta Otolaryngol. 2013;133(5):538–43.CrossRefPubMed
38.
Valmary-Degano S, Jacquin E, Pretet JL, et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol. 2013;44(6):992–1002.CrossRefPubMed
39.
Jung AC, Job S, Ledrappier S, et al. A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis. Clin Cancer Res. 2013;19(15):4174–84.CrossRefPubMed
40.
Melkane AE, Auperin A, Saulnier P, et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck. 2014;36(2):257–65.CrossRefPubMed
41.
Melkane AE, Mirghani H, Auperin A, et al. HPV-related oropharyngeal squamous cell carcinomas: a comparison between three diagnostic approaches. Am J Otolaryngol. 2014;35(1):25–32.CrossRefPubMed
42.
Arana R, Flejou JF, Si-Mohamed A, Bauer P, Etienney I. Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Dis. 2015;17(11):965–72.CrossRefPubMed
43.
Fonmarty D, Cherriere S, Fleury H, et al. Study of the concordance between p16 immunohistochemistry and HPV-PCR genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(3):135–9.CrossRefPubMed
44.
Hanns E, Job S, Coliat P, et al. Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncol. 2015;51(9):848–56.CrossRefPubMed
45.
Ou D, Levy A, Blanchard P, et al. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role? Oral Oncol. 2016;59:50–7.CrossRefPubMed
46.
Bauduer F, Katsahian S, Blanchard Y, Oui B, Capdupuy C, Renoux M. Descriptive epidemiology of non-Hodgkin lymphomas in a southwestern French hematology center: absence of significant relationship with hepatitis C virus infection. Hematol Cell Ther. 1999;41(5):191–3.CrossRefPubMed
47.
Germanidis G, Haioun C, Pourquier J, et al. Hepatitis C virus infection in patients with overt B-cell non-Hodgkin’s lymphoma in a French center. Blood. 1999;93(5):1778–9.PubMed
48.
Seve P, Renaudier P, Sasco AJ, et al. Hepatitis C virus infection and B-cell non-Hodgkin’s lymphoma: a cross-sectional study in Lyon, France. Eur J Gastroenterol Hepatol. 2004;16(12):1361–5.CrossRefPubMed
49.
Le Bail B, Faouzi S, Boussarie L, et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol. 1999;189(1):46–52.CrossRefPubMed
50.
Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120(7):1763–73.CrossRefPubMed
51.
Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology. 2002;36(3):692–701.CrossRefPubMed
52.
Borie F, Bouvier AM, Herrero A, et al. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol. 2008;98(7):505–9.CrossRefPubMed
53.
Pineau P, Marchio A, Battiston C, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653(1–2):6–13.CrossRefPubMed
54.
Brousset P, Chittal S, Schlaifer D, et al. Detection of Epstein–Barr virus messenger RNA in Reed-Sternberg cells of Hodgkin’s disease by in situ hybridization with biotinylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections. Blood. 1991;77(8):1781–6.PubMed
55.
Delsol G, Brousset P, Chittal S, Rigal-Huguet F. Correlation of the expression of Epstein–Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin’s disease. Am J Pathol. 1992;140(2):247–53.PubMedPubMedCentral
56.
Brousset P, Rochaix P, Chittal S, Rubie H, Robert A, Delsol G. High incidence of Epstein–Barr virus detection in Hodgkin’s disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology. 1993;23(2):189–91.CrossRefPubMed
57.
Martel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I. Qualitative analysis of the expression of Epstein–Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol. 1995;76(Pt 6):1401–8.CrossRefPubMed
58.
Belkaid MI, Briere J, Djebbara Z, Beldjord K, Andrieu JM, Colonna P. Comparison of Epstein–Barr virus markers in Reed–Sternberg cells in adult Hodgkin’s disease tissues from an industrialized and a developing country. Leuk Lymphoma. 1995;17(1–2):163–8.CrossRefPubMed
59.
Brousset P, Benharroch D, Krajewski S, et al. Frequent expression of the cell death-inducing gene Bax in Reed–Sternberg cells of Hodgkin’s disease. Blood. 1996;87(6):2470–5.PubMed
60.
Drouet E, Brousset P, Fares F, et al. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin’s disease. J Med Virol. 1999;57(4):383–9.CrossRefPubMed
61.
Besson C, Roetynck S, Williams F, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin’s lymphoma in a familial study. PLoS ONE. 2007;2(5):e406.CrossRefPubMedPubMedCentral
62.
Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113(12):2765–3775.CrossRefPubMed
63.
Ghesquieres H, Maurer MJ, Casasnovas O, et al. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. Cytokine. 2013;64(2):523–31.CrossRefPubMedPubMedCentral
64.
De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer. 2009;45(15):2632–9.CrossRefPubMed
65.
González C, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2012;23(5):1320–4.CrossRefPubMed
66.
Sharma S, Carballo M, Feld JJ, Janssen HL. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515–22.CrossRefPubMed
67.
Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48(2):200–7.CrossRefPubMed
68.
Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5):S5–16.CrossRefPubMed
69.
70.
Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein–Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol. 2012;53(3):195–200.CrossRefPubMed
71.
Institut De Veille Sanitaire. Estimation des couvertures vaccinales en secteur libéral à travers l’échantillon généraliste des bénéficiaires en France—2004–2009. Saint-Maurice: Institut De Veille Sanitaire; 2010.
72.
Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine. 2011;29(19):3610–6.CrossRefPubMed
73.
Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747–55.CrossRefPubMed
74.
Thibault V, Laperche S, Thiers V, et al. Molecular epidemiology and clinical characteristics of hepatitis B identified through the French mandatory notification system. PLoS ONE. 2013;8(9):e75267.CrossRefPubMedPubMedCentral
75.
Yang T, Cairns BJ, Reeves GK, Green J, Beral V. Cancer risk among 21st century blood transfusion recipients. Ann Oncol. 2017;28(2):393–9.PubMed
76.
Aherfi S, Colson P, Audoly G, et al. Marseillevirus in lymphoma: a giant in the lymph node. Lancet Infect Dis. 2016;16(10):e225–34.CrossRefPubMed
77.
Chang M-H, You S-L, Chen C-J, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.CrossRefPubMed
78.
Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3(5):e138.CrossRefPubMedPubMedCentral
79.
Balinska MA. Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates? J Clin Virol. 2009;46(3):202–5.CrossRefPubMed
80.
Agence Nationale d’Accréditation et d’Évaluation en Santé, Institut national de la santé et de la recherche médicale. Consensus conference: vaccination against the hepatitis B virus 10–11 September 2003 Xavier-Bichat Medical School—Paris: Guidelines. Saint-Denis, France: Agence Nationale d’Accréditation et d’Évaluation en Santé; 2004.
81.
Fonteneau L, Ragot M, Guthmann J-P, Lévy-Bruhl D. Use of health care reimbursement data to estimate vaccination coverage in France: example of hepatitis B, meningitis C, and human papillomavirus vaccination. Rev Epidemiol Sante Publ. 2015;63(5):293–8.CrossRef
82.
Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–8.CrossRefPubMed
83.
Brotherton J, Murray SL, Hall MA, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199(9):614–7.CrossRefPubMed
84.
Public Health England. Human Papillomavirus (HPV) vaccination coverage in adolescent females in England: 2015/16. London: Public Health England; 2016.
85.
Institut De Veille Sanitaire. Modélisation médico-économique de l’impact de l’organisation du dépistage du cancer du col utérin et de l’introduction de la vaccination contre les HPV dans le calendrier vaccinal. Saint-Maurice: Institut De Veille Sanitaire; 2007.
86.
Haesebaert J, Lutringer-Magnin D, Kalecinski J, et al. French women’s knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14–18 year old daughters: a quantitative-qualitative study. BMC Public Health. 2012;12(1):1034.CrossRefPubMedPubMedCentral
87.
Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction–the first five years. Vaccine. 2012;30:F139–48.CrossRefPubMed
88.
Haut Conseil de santé publique. Avis relatif à la révision de l’âge de vaccination contre les infections à papaillomavirus humains des jeunes filles. Paris: Haut Conseil de Santé Publique; 2012.
89.
Haut Conseil de la Santé Publique. Vaccination des garçons contre les infections à papillomavirus. Paris: Haut Conseil de la Santé Publique; 2016.
90.
Centres for Disease Control and Prevention. HPV vaccines: vaccinating your preteen or teen. Atlanta: Centres for Disease Control and Prevention; 2017.
91.
Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443–50.CrossRefPubMed
92.
Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.CrossRefPubMedPubMedCentral
93.
Piroth L, Rabaud C, Rey D, et al. Hepatitis C: the path towards effective universal therapy. Lancet. 2016;388(10049):1051–2.CrossRefPubMed
94.
Czernichow P. Hépatites b et c: mieux savoir pour mieux agir. Bull Epidemiol Hebd. 2016;13–14:222–3.
95.
Bottero J, Brouard C, Roudot-Thoraval F, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int. 2016;36(10):1442–9.CrossRefPubMed
96.
Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772–81.CrossRefPubMed
97.
Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42.CrossRefPubMed
Metadata
Title
New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis
Authors
Kevin David Shield
Claire Marant Micallef
Catherine de Martel
Isabelle Heard
Francis Megraud
Martyn Plummer
Jérôme Vignat
Freddie Bray
Isabelle Soerjomataram
Publication date
01-03-2018
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 3/2018
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-017-0334-z

Other articles of this Issue 3/2018

European Journal of Epidemiology 3/2018 Go to the issue

METHODS

Horizontal mixture model for competing risks: a method used in waitlisted renal transplant candidates

ESSAY

Epidemiology in wonderland: Big Data and precision medicine

CANCER

Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000–2015)

COMMENTARY

Human papillomavirus vaccine: Urgent need to promote gender parity

NEW STUDY

The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries

LETTER TO THE EDITOR

Sauna bathing and systemic inflammation